C07D 249/02
Not condensed with other rings
Official title: not condensed with other rings
C07D249/02 (Not condensed with other rings) appears on 7,061 US grants and 4,123 published applications in this corpus.
Search patents in C07D- Granted patents
- 7,061
- Published applications
- 4,123
- Assignees
- 1,833
- Inventors
- 15,196
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 92 | 0 |
| 1977 | 93 | 0 |
| 1978 | 97 | 0 |
| 1979 | 77 | 0 |
| 1980 | 100 | 0 |
| 1981 | 117 | 0 |
| 1982 | 105 | 0 |
| 1983 | 108 | 0 |
| 1984 | 113 | 0 |
| 1985 | 151 | 0 |
| 1986 | 162 | 0 |
| 1987 | 140 | 0 |
| 1988 | 166 | 0 |
| 1989 | 202 | 0 |
| 1990 | 226 | 0 |
| 1991 | 203 | 0 |
| 1992 | 216 | 0 |
| 1993 | 200 | 0 |
| 1994 | 156 | 0 |
| 1995 | 158 | 0 |
| 1996 | 174 | 0 |
| 1997 | 188 | 0 |
| 1998 | 178 | 0 |
| 1999 | 176 | 0 |
| 2000 | 157 | 0 |
| 2001 | 183 | 39 |
| 2002 | 219 | 174 |
| 2003 | 196 | 273 |
| 2004 | 130 | 319 |
| 2005 | 142 | 206 |
| 2006 | 164 | 174 |
| 2007 | 131 | 150 |
| 2008 | 97 | 138 |
| 2009 | 101 | 153 |
| 2010 | 134 | 188 |
| 2011 | 111 | 173 |
| 2012 | 138 | 151 |
| 2013 | 130 | 155 |
| 2014 | 154 | 198 |
| 2015 | 155 | 177 |
| 2016 | 135 | 185 |
| 2017 | 151 | 178 |
| 2018 | 126 | 143 |
| 2019 | 108 | 117 |
| 2020 | 119 | 147 |
| 2021 | 108 | 149 |
| 2022 | 77 | 124 |
| 2023 | 87 | 135 |
| 2024 | 80 | 110 |
| 2025 | 79 | 100 |
| 2026 | 51 | 67 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Substituted 1,2,3-triazoles as antibacterial and antifungal pleuromutilin conjugates6 Oct 2026US 12,753,177 B2Syddansk Universittet
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Lipoxygenase inhibitors22 Sep 2026US 12,741,926 B2SRI International
- Composition for prevention or treatment of neurofibromatosis type 2 syndrome22 Sep 2026US 12,741,946 B2Prg S&Tech Inc.
- Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xpo1 inhibitors8 Oct 2026US 2026/0308132 A1Karyopharm Therapeutics Inc.
- Compounds useful for in vivo imaging of protein oxidation and/or cancer treatment1 Oct 2026US 2026/0295098 A1Wake Forest University Health Sciences
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Synthetic methods of making (2h-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators1 Oct 2026US 2026/0297096 A1Janssen Pharmaceutica NV
- 3,5-diaminotriazole derivatives and uses thereof for treating ocular diseases24 Sep 2026US 2026/0284014 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Pyrrolidine-containing monomers and oligomers675US 5,519,134 AIsis Pharmaceuticals, Inc. · 1996
- Alkynyl and azido-substituted 4-anilinoquinazolines379US 5,747,498 APfizer Inc. · 1998
- Copper-catalysed ligation of azides and acetylenes267US 7,375,234 B2The Scripps Research Institute · 2008
- Substituted biphenyl isoxazole sulfonamides222US 5,612,359 ABristol-Myers Squibb Company · 1997
- Nitrogen containing heteroaromatics as factor Xa inhibitors211US 6,020,357 ADuPont Pharmaceuticals Company · 2000